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Multiple cytokines and inflammatory markers control TB infection. We aimed to investigate the changes 
in multiple cytokines and inflammatory markers in active TB patients following anti-TB drug therapy. 
Twenty-nine patients with active TB were recruited prospectively between December 2010 and July 
2017. Blood samples were collected before (T0), after 2 months (T2), and at the end of anti-TB treatment 
(Tend). We measured the levels of Interferon (IFN)-γ, interleukin (IL)-2, IL-12, IL-10, IL-13 and tumor 
necrosis factor (TNF)-α in supernatants collected from the QuantiFERON-TB Gold In-Tube assay (QFT-
GIT), as well as the WBC, neutrophil, platelet count and neutrophil to lymphocyte ratio (NLR) in whole 
blood. Compared with baseline levels, WBC, neutrophil, and platelet counts were significantly lower 
following treatment. In addition, the NLR after treatment significantly decreased compared with 
baseline, whereas the IL-2/IFN-γ ratio increased after treatment. In conclusion, the levels of IL-2/IFN-γ 
ratios in the supernatant and the NLR might be useful biomarkers to evaluate the effectiveness of drug 
therapy in active TB patients.
Tuberculosis remains a major cause of death and morbidity worldwide, responsible for an estimated 1.7 million 
deaths each year1. Prolonged treatment is required for adequate therapy, resulting in significant costs and medical 
resources.
The ability to monitor the response of TB to therapy and confirm adequate treatment would constitute a major 
advancement. There have been efforts to develop biomarkers for the diagnosis and treatment of TB. Identifying 
biomarkers of treatment success might provide insight into surrogate markers of protective immunity against TB. 
Cell-mediated immunity plays an important role in human host defenses against TB2. The essential role of T cells 
in protection against TB infection has been well-documented2. IFN-γ, a cytokine produced by T cells, is used to 
diagnose TB infection3. Other cytokines, including TNF-α4, IL-125, IL-136, and IL-27 are essential in controlling 
TB infection. Furthermore, IFN-γ and IL-2 profiles have been associated with antigenic load and treatment in 
active TB8.
Although several studies have evaluated IFN-γ to monitor the response to anti-TB treatment, these stud-
ies yielded conflicting results, with IFN-γ responses decreasing9–11, increasing12, or remaining not significantly 
changed13,14 in response to treatment. An in vitro IFN- γ immune diagnostic assay for active TB disease, the nov-
elty of which consists of the use of multiepitopic region of difference (RD)1 peptides selected by computational 
analysis was reported15–17. In the study of Goletti et al., the response to selected RD1 peptides was associated with 
TB disease in HIV-infected individuals, and decreased after successful therapy9. Several exploratory studies have 
evaluated the diagnostic potential of cytokine biomarkers other than IFN-γ for monitoring anti-TB treatment 
such as TNF-α18, or IFN- γ /TNF-α19, or IFN- γ inducible protein (IP)-1020.
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However, no single cytokine or combination of cytokines has shown a strong correlation with treatment suc-
cess. To date, relatively few studies have evaluated the usefulness of multiple cytokines in monitoring the response 
to anti-TB treatment21,22. Previously, we examined multiple cytokines, including IFN-γ and IL-2, to determine the 
TB infection status and assess mycobacterial loads among smear-positive, smear-negative, and latent TB infec-
tion23. In the current study, we investigated the changes in multiple cytokines and inflammatory markers in active 
TB patients following anti-TB drug therapy.
Materials and Methods
Study population. Patients with active pulmonary TB were recruited prospectively between December 2010 
and July 2017 at Severance Hospital, a tertiary referral hospital in Seoul, South Korea, after approval of the study 
protocol by the Ethics Review Committee. The patients who could not be followed for at least 6 months, those 
with HIV infection, end-stage renal disease, or leukemia/lymphoma, and those undergoing immunosuppressive 
therapy within 3 months of enrollment were excluded. After providing informed consent, each patient completed 
a set of questionnaires pertaining to demographics, history of TB, and cigarette use. The QFT-GIT was performed 
in each patient T0, T2, and Tend. We also measured the levels of IFN-γ, IL-2, IL-12 (p40), IL-10, IL-13, and TNF-α 
in the supernatant obtained from the QFT-GIT, as well as the white blood cell (WBC) count, neutrophil count, 
lymphocyte count, platelet count, red cell distribution width (RDW), mean platelet volume, neutrophil to lym-
phocyte ratio (NLR), the ratio of monocytes and lymphocytes (MLR) and platelet to lymphocyte ratio (PLR) in 
all patients at T0, T2, and Tend.
All participants provided a written, informed consent for the collection of samples and subsequent analysis. 
All the individuals participating in this study were over 18 years old. All methods were carried out in accordance 
with relevant guidelines and regulations. The study protocol was reviewed and approved by the Institutional 
Review Board of Yonsei University Health Service, Severance Hospital (4-2013-0803).
Diagnosis and TB treatment. The diagnosis of active pulmonary TB was made based on clinical, radio-
logical, microbiological, and pathological data. Active pulmonary TB was confirmed in TB cultures derived from 
respiratory specimens or by the presence of caseating granulomas in lung tissue. One patient who was highly 
suspected of having active TB but had a negative mycobacterial culture showed good clinical and radiographic 
responses to TB treatment and therefore was also included. Treatment was based on the Korean Guidelines for 
Tuberculosis 2011. The standard regimen of rifampicin (10 mg/kg body weight [BW]/day), isoniazid (5 mg/kg 
BW/day), ethambutol (15–25 mg/kg BW/day), and pyrazinamide (15–30 mg/kg BW/day) was used. The dura-
tion of treatment was at least 6 months, depending on the risk of recurrence, the clinical response to treatment, 
and drug intolerance. Patients who had positive mycobacterial culture at the end of the intensive phase (after 
two months of the treatment) with cavity lesion in their chest radiograph were considered as having high risk of 
relapse.
QFT-GIT assay. IFN-γ release assays were performed using the QFT-GIT assay kit according to the manu-
facturer’s instructions. Whole blood (1 mL) was collected in each of three tubes precoated with saline (nil con-
trol, Nil), TB-specific antigen (TB Ag; ESAT-6, CFP-10, and TB7.7), or mitogen and incubated for 20 h at 37 °C 
within 8 h of blood sampling. The plasma supernatant was collected after centrifugation and stored at −20 °C 
until assayed for IFN-γ using the QFT GOLD ELISA. Results were calculated using the manufacturer’s QFT-GIT 
software.
Multiplex analysis of cytokine production. The levels of multiple cytokines, IFN-γ, IL-2, IL-12(p40), 
IL-10, IL-13, and TNF-α, in the supernatants obtained from the QFT-GIT assays were measured using the com-
mercial MILLIPLEX® MAP human cytokine/chemokine kit (HCYTOMAG-60K-06, Millipore, Billerica, MA, 
USA) with fluorescently labeled microsphere beads and a Luminex reader. The cytokine levels were measured in 
the QFT-GIT supernatants at T0, T2, and Tend. The undiluted supernatants were used in this study. The minimum 
detectable concentrations were 0.8 pg/mL for IFN-γ, 1.0 pg/mL for IL-2, 7.4 pg/mL for IL-12(p40), 1.1 pg/mL for 
IL-10, 1.3 pg/mL for IL-13, and 0.8 pg/mL of TNF-α according to the protocol. The value under minimum detect-
able concentrations were considered as zero.
Statistical analysis. The quantitative data for cytokines were expressed as numbers with percentage 
in brackets or as medians with the interquartile range (IQR) in brackets. Cytokine levels were analyzed using 
repeated measures analysis of variance to compare the expression of each cytokine among three groups. The 
Wilcoxon signed rank test was used to compare cytokine expression between two related groups. The GraphPad 
Prism program version 4.0 (GraphPad software, San Diego, CA, USA) was used to create the graphics. A 
two-tailed p-value < 0.05 was considered significant. All statistical analyses were performed using SPSS version 
15.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline patient characteristics. The clinical characteristics of the study patients, including the extent 
of the disease in chest CT, acid-fast bacilli (AFB) smear and culture positivity, and profiles obtained from the 
blood tests and QFT-GIT assay, are summarized in Table 1. Twenty-two (75.9%) patients were culture-positive on 
sputum specimens, and all 22 achieved sputum conversion. The median (IQR) level of the IFN-γ concentration 
obtained in the TB Ag tube in all patients was 9.47 (4.51–10.0) IU (international units)/mL.
Multiple cytokine responses to TB –specific antigens before, after 2 months, and after treat-
ment of active pulmonary TB. We measured the levels of multiple cytokines at the major time points 
of anti-TB treatment for active pulmonary TB (Fig. 1). The response was calculated by subtracting the level in 
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the Nil sample from that in the TB Ag sample. The mean changes from T0 to Tend of IFN-γ, IL-10, IL-12, IL-13, 
IL-2 and TNF-α were −770.21 pg/ml (95% CI, −1150.72 to −389.69), −7.52 pg/ml (95% CI, −14.05 to −1.00), 
−1.80 pg/ml (95% CI, −7.17 to 3.57), −5.09 pg/ml (95% CI, −21.39 to 11.20), −118.37 pg/ml (95% CI, −180.69 
to −56.05), and −176.36 pg/ml (95% CI, −389.22 to 36.48). The proportions of subjects that achieved these 
change for IFN-γ, IL-10, IL-12, IL-13, IL-2, and TNF-α were 65.5%, 68.9%, 55.1%, 62.0%, 58.6%, and 62.0%.
The median decreases in IFN-γ, IL-10, IL-12, IL-13, IL-2, and TNF-α levels were not significant (Fig. 1). In 
addition the mean changes from T0 to Tend of IL-2/IFN-γ ratio and IL-10/IFN-γ were 0.19 (95% CI, 0.07 to 0.30) 
and 0.12 (95% CI, −0.15 to 0.41). The proportions of subjects that achieved these change for IL-2/IFN-γ ratio 
and IL-10/IFN-γ were 24.1% and 27.5%. The IL-2/IFN-γ ratio measured in the supernatant after treatment was 
significantly increased compared with baseline (P = 0.018), whereas the median decrease in IL-10/IFN-γ ratio 
not significant (Fig. 2).
Inflammatory markers in peripheral blood before, at 2 months, and after treatment of active 
pulmonary TB. The mean changes from T0 to Tend of WBC, neutrophil, lymphocyte, monocyte, platelet, MPV, 
and RDW were −1.93 × 103/μL (95% CI, −2.64 to −1.22), −1.77 × 103/μL (95% CI, −2.44 to −1.09), 0.03 × 103/
μL (95% CI, −0.13 to 0.19), −0.05 × 103/μL (95% CI, −0.12 to 0.01), −80.75 × 103/μL (95% CI, −110.80 to 
−50.71), 0.77 fL (95% CI, 0.24 to 1.30), and −0.41% (95% CI, −1.16 to 0.34). The proportions of subjects that 
achieved these change for WBC, neutrophil, lymphocyte, monocyte, platelet, MPV, and RDW were 55.1%, 57.1%, 
42.8%, 53.5%, 58.6%, 35.7%, and 64.2%. Compared with baseline levels, the WBC, neutrophil, and platelet counts 
decreased in response to treatment (P = 0.0001, P = 0.0005, and P = 0.001, respectively) (Fig. 3). The decreases 
in the median lymphocyte count and monocyte count were not statistically significant (Fig. 3). In addition, The 
Total (N = 29)
Age, median (IQR) 27 (25–38)
Male, n (%) 16 (55.1)





 weight loss 3 (10.3)
 fatigue 9 (31.0)




Chest CT finding, n (%)
 centrilobular 9 (31.0)
 consolidation 11 (37.9)
 cavity + centrilobular 8 (27.6)
 mass 1 (3.4)
Extent of the disease in chest CT, the number of lobes (%)
 One lobe 20 (69.0)
 2–3 lobes 9 (31.0)
 >3 lobes 0
Blood tests, median (IQR)
 WBC count (/µL) 6990.0 (5750.0–8380.0)
 Hemoglobin level (g/dL) 13.8 (12.3–14.9)
 Platelet count (×103/µL) 292.0 (251.0–387.0)
Sputum exam, n (%)
 AFB smear, positive 3 (10.3)
 TB culture, positive 22 (75.9)
 sputum conversion 22 (100.0)
QFT-GIT assay, median (IQR)
 Nil 0.21 (0.13–0.28)
 TB Ag 9.47 (4.51–10.00)
 mitogen 10.00 (10.00–10.00)
 TB Ag-Nil 8.6 (4.2–10.00)
Extrapulmonary TB, n (%) 1 (3.4)
Table 1. Demographics and clinical data.
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Figure 1. The changes of levels of IFN-γ, IL-10, IL-12, IL-13, IL-2 and TNF-α in supernatants of QFT-GIT 
before (T0), after 2 months (T2), and at the end of anti-TB treatment (Tend).
Figure 2. The changes of IL-2/IFN-γ and IL-10/IFN-γ ratios in supernatant of QFT-GIT during anti-TB 
treatment.
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mean changes from T0 to Tend of NLR, PLR, and MLR were −1.34 (95% CI, −1.99 to −0.69), −59.21 (95% CI, 
−95.90 to −22.52), and −0.04 (95% CI, −0.09 to 0.01). The proportions of subjects that achieved these change 
for NLR, PLR, and MLR were 67.8%, 60.7%, and 64.2%. The NLR after treatment was significantly decreased 
compared with baseline (P = 0.002) (Fig. 4). The PLR and MLR were not significantly changed (Fig. 4).
Discussion
This study investigated the changes in multiple cytokine and inflammatory markers in 29 patients with active TB 
following anti-TB drug therapy. We found that the WBC, neutrophil, and platelet counts were decreased follow-
ing anti-TB drug therapy. The IL-2/IFN-γ ratio and NLR were significantly increased after treatment compared 
with baseline.
Figure 3. The changes of serum inflammatory markers during anti-TB treatment.
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Several exploratory studies have evaluated the potential of cytokine biomarkers other than IFN-γ, particu-
larly TNF-α, IL-2, IL-10, and IL-12, for monitoring anti-TB therapy. TNF-α has been one of the most studied 
cytokines in previous studies. The largest of these studies, by Eum et al., found that TNF-α levels were increased 
during anti-TB treatment18. However, most studies on TB-Ag-stimulated TNF-α responses to anti-TB treatment 
have consistently reported a reduction in TNF-α levels in whole blood or peripheral blood mononuclear cells 
during treatment19,24–26. Those results were not consistent with the findings of our study. However, our study is 
different in that these markers were investigated in supernatants collected from the QFT-GIT.
IL-10 is an important anti-inflammatory cytokine reported to affect multiple cell types, such as macrophages, 
monocytes, dendritic cells, CD4+ T cells, and CD8+ T cells27. It inhibits CD4+ T cell responses by inhibiting 
the antigen-presenting cell function of TB-infected cells28. Recently, the secretion of Mycobacterium tuberculosis 
(MTB)-enhanced intracellular survival protein from MTB cells was reported, which possibly increases IL-10 
expression29. Of the studies that have evaluated the role of IL-10 in TB infection, the findings are not consist-
ent18,30–32. The study by Eum et al. reported that IL-10 levels increased with treatment18. However, another large 
longitudinal study by Sai Priya et al. found a reduction in IL-10 levels in response to treatment30. In the current 
study, we found IL-10 responses to TB specific antigens showed the tendency of decrement following anti-TB 
therapy. This decrease may be due to modified cytokine expression in infected individuals after treatment.
Several studies have assessed the role of IL-2, which is produced by TB-specific polyfunctional T cells, in 
monitoring anti-TB treatment responses. Two studies reported lower IL-2 levels at the end compared with the 
start of treatment19,33. Furthermore, Mattos et al. reported an increase in IL-2-producing TB-specific T-cells dur-
ing treatment34. In the current study, the changes observed in IL-2 levels were not significant during treatment. 
However, the IL-2/IFN-γ ratio was significantly increased after treatment. Thus, evaluation of a combination 
of cytokine biomarkers might be the alternative way to monitor the treatment responses instead of the single 
cytokine response. Simultaneous measurements of IFN-γ and IL-2 levels help determine T cell cytokine profiles, 
which reflect the memory phenotype and comprise three main functional T cell subsets: effector cells secreting 
primarily IFN-γ only, effector memory cells secreting primarily both IFN-γ and IL-2, and central memory cells 
secreting IL-2 only35. Casey et al. stated that the proportion of ESAT-6/CFP-10-specific cells secreting IFN-γ only 
was decreased during treatment. Conversely, the proportion of ESAT-6/CFP-10-specific IFN-γ/IL-2-secreting 
cells was increased36. The increased IL-2/IFN-γ ratio found in our study can be explained by the dynamics of 
TB-specific T cells.
Several studies have investigated the responses of IL-12 during anti-TB treatment. Eum et al. found an increase 
in IL-12 levels after 2 months of treatment, followed by a decrease to baseline levels after 6 months18, whereas Sai 
Priya et al. found a reduction in IL-12 levels over the treatment course30. In the current study, the decrease in 
median IL-12 levels was not statistically significant.
Inflammation plays a significant role in the pathogenesis of pulmonary TB. Recently, the relationships 
between inflammatory markers, such as neutrophil and platelet counts, and TB have been reported. Several stud-
ies demonstrated an important contribution of poly-morphonuclear neutrophils (PMN) to the pathogenesis of 
TB. Eum et al. identified PMNs as the primary immune cell population in sputum and bronchoalveolar lavage 
(BAL) samples from patients infected with active pulmonary TB37. Furthermore, PMN in sputum, BAL, and pul-
monary cavity samples carried the greatest mycobacterial loads37.
The NLR has emerged as a biomarker of inflammation38,39. There are several studies regarding the relationship 
between chronic obstructive pulmonary disease, TB, or pneumonia and the NLR38,40–43. Iliaz et al. found a higher 
NLR in patients with advanced pulmonary TB as opposed to patients with mild to moderate pulmonary TB38. 
Additionally, Abakay et al. found reported a significantly higher WBC count, neutrophil count, RDW, and NLR in 
patients with advanced pulmonary TB compared with mild to moderate pulmonary TB44. However, the change in 
the NLR in TB patients following anti-TB therapy has not been fully evaluated. In the current study, we found that 
the NLR was significantly decreased after treatment compared with baseline. The NLR is easily determined from 
routine laboratory tests and is easier and less expensive to measure compared with other inflammatory biomark-
ers. Therefore, the NLR might be used as a biomarker to evaluate the response to anti-TB treatment.
There are several limitations to this study. First, the number of participants was relatively small, and cases of 
relapse or treatment failure were not analyzed in this study. Further prospective cohort studies involving larger 
study samples with variable treatment outcomes are needed. More validation studies are needed in the future 
which are conducted in other settings. Second, several potential biomarkers such as IP-10, monocyte chemotactic 
protein 2, and epidermal growth factor were not measured in this study. The studies for other candidate markers 
Figure 4. The changes of neutrophil to lymphocyte, platelet to lymphocyte, and monocyte to lymphocyte ratios 
during anti-TB treatment.
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or sample types other than Quantiferon supernatants are needed in the future. Third, because of the small num-
bers of subjects and the absence of a drug resistant cohort, subjects with non-TB pneumonia were not studied as 
a control group. Further prospective studies involving subjects with non-TB pneumonia are needed.
In conclusion, the current study showed that WBC, neutrophil, and platelet counts were decreased following 
anti-TB therapy. The IL-2/IFN-γ ratio and the NLR might be potential biomarkers to evaluate the effectiveness of 
drug therapy in active TB patients.
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